```html

Veno‑occlusive Disease (VOD) – Comprehensive Medical Guide

Overview

Veno‑occlusive disease (VOD), also called sinusoidal obstruction syndrome (SOS), is a potentially life‑threatening condition in which the small veins (sinusoids) that drain blood from the liver become inflamed, blocked, and scarred. This blockage impedes normal blood flow, leading to liver enlargement, fluid accumulation, and in severe cases, multi‑organ failure.

Who it affects

• Hematopoietic stem‑cell transplant (HSCT) recipients – VOD is most common after high‑dose chemotherapy or total body irradiation used for bone‑marrow transplantation.
• Patients receiving certain chemotherapy agents (e.g., busulfan, cyclophosphamide, melphalan) or targeted drugs (e.g., inotuzumab ozogamicin).
• Infants and young children with inherited metabolic liver diseases (e.g., hereditary tyrosinemia type 1).
• Rarely, adults with non‑transplant‑related liver injury (e.g., sepsis, hepatic graft‑versus‑host disease).

Prevalence

• In adult allogeneic HSCT, VOD occurs in 5‑15 % of patients; incidence is higher (up to 30 %) after myeloablative regimens that include busulfan.<sup>[1] NIH, 2023</sup>
• In pediatric HSCT, rates range from 10‑20 %, with infants under 1 year at the highest risk.<sup>[2] WHO, 2022</sup>
• Non‑transplant VOD is much rarer, accounting for < 0.5 % of all liver diseases.<sup>[3] Mayo Clinic, 2023</sup>

Symptoms

Symptoms usually develop within 21 days after the conditioning regimen, but delayed presentations up to 30 days are possible. The classic “triad” includes:

1. Rapid weight gain (≥5 % of baseline) from fluid retention

Caused by ascites and generalized edema.

2. Hepatomegaly (enlarged liver)

Usually palpable 2–5 cm below the right costal margin; may be tender.

3. Ascites

Fluid accumulation in the abdomen detected clinically or by ultrasound.

Additional symptoms

• Right upper quadrant or epigastric pain – often described as a dull ache.
• Jaundice – yellowing of the skin and sclera due to elevated bilirubin.
• Elevated liver enzymes – AST, ALT, and alkaline phosphatase rise.
• Kidney dysfunction – oliguria or rising creatinine in severe cases.
• Coagulopathy – prolonged PT/INR, low platelets, increased bleeding tendency.
• Respiratory distress – from pleural effusions or pulmonary edema.
• Fever – may suggest concurrent infection.

Causes and Risk Factors

VOD results from direct toxic injury to sinusoidal endothelial cells, followed by fibrin deposition, sinusoidal narrowing, and ultimately obstruction.

Primary causes

• High‑dose chemotherapy – especially alkylating agents (busulfan, cyclophosphamide, melphalan).
• Total body irradiation (TBI) – damages the hepatic microvasculature.
• Immunosuppressive drugs – e.g., sirolimus, tacrolimus, when combined with other risk factors.
• Graft‑versus‑host disease (GVHD) – hepatic involvement can precipitate VOD.
• Inborn errors of metabolism – e.g., hereditary tyrosinemia type 1 (treated with nitisinone).

Risk factors

• Age < 2 years (infants) or > 60 years.
• Pre‑existing liver disease (cirrhosis, hepatitis).
• Elevated baseline bilirubin (> 2 mg/dL).
• High cumulative dose of busulfan (> 12 mg/kg) or cyclophosphamide (> 120 mg/kg).
• Recent use of hepatotoxic medications (e.g., azoles, pyrrolizidine‑alkaloid‑containing herbs).
• Genetic polymorphisms in glutathione‑S‑transferase (GST) genes.
• Radiation to the liver field.
• Severe infections or sepsis around the time of transplantation.

Diagnosis

Early recognition is critical; diagnosis relies on clinical criteria supported by imaging and laboratory studies.

Clinical criteria

The most widely used are the modified Seattle and Baltimore criteria. A simplified version:

• Two of the following within 30 days post‑transplant:
  • Weight gain ≥5 %.
  • Hepatomegaly.
  • Ascites.
• Or, any one of the above plus bilirubin ≥2 mg/dL.

Laboratory tests

• Complete metabolic panel – elevated bilirubin, AST/ALT, alkaline phosphatase.
• Coagulation profile – PT/INR, fibrinogen, D‑dimer.
• Renal function – serum creatinine, urine output.
• Serum lactate dehydrogenase (LDH) – often markedly increased.

Imaging

• Ultrasound with Doppler – shows reversed or reduced portal vein flow, hepatic vein narrowing, and ascites.
• CT or MRI – may demonstrate heterogeneous hepatic enhancement and peri‑portal edema; used when ultrasound is inconclusive.
• Transient elastography (FibroScan) – can quantify liver stiffness, correlating with severity.

Biopsy (rarely performed)

Core liver biopsy is the definitive test, showing sinusoidal congestion, endothelial loss, and fibrosis. It is reserved for atypical cases because of bleeding risk.

Treatment Options

Management combines supportive care, disease‑specific pharmacotherapy, and, in severe cases, advanced interventions.

Supportive care

• Fluid balance monitoring – restrict excess fluids; use diuretics (furosemide + spironolactone) to control ascites.
• Albumin infusions for hypoalbuminemia and to maintain oncotic pressure.
• Transfusion support – packed RBCs for anemia, platelets for thrombocytopenia.
• Nutritional support – high‑protein, low‑sodium diet; consider parenteral nutrition if oral intake limited.
• Infection prophylaxis – broad‑spectrum antibiotics/antifungals per transplant protocol.

Targeted pharmacologic therapy

• Defibrotide (approved by FDA/EMA for severe VOD):
  • Mechanism – promotes fibrinolysis, protects endothelial cells, and reduces thrombotic micro‑angiopathy.
  • Dosage – 6.25 mg/kg IV every 6 hours for a minimum of 21 days or until resolution.
  • Evidence – Phase III trial showed 38 % survival at day 100 vs 25 % with historical controls.<sup>[4] Lancet Haematology, 2022</sup>
  • Adverse effects – bleeding, hypotension; monitor CBC and coagulation.
• Antithrombotic agents – low‑dose heparin or prostacyclin have been studied but are not standard due to bleeding risk.
• Corticosteroids – may be used to treat coexistent GVHD but do not treat VOD directly.

Procedural interventions

• Therapeutic paracentesis – relieves tense ascites; replace fluid losses with albumin.
• Transjugular intrahepatic portosystemic shunt (TIPS) – creates a channel to bypass obstructed sinusoids; considered in refractory cases when liver function is relatively preserved.
• Renal replacement therapy (RRT) – for acute kidney injury secondary to VOD.

Experimental / emerging therapies

• Gene‑silencing agents targeting GST pathways (early‑phase trials).
• Mesenchymal stem‑cell infusions – potential endothelial repair; data still limited.

Living with Veno‑occlusive disease (VOD)

Even after acute management, many patients require ongoing care to prevent recurrence and manage chronic liver changes.

Daily management tips

• Fluid monitoring – weigh yourself each morning; a gain > 0.5 kg may signal worsening ascites.
• Low‑sodium diet – aim for < 2 g/day to reduce fluid retention.
• Medication adherence – never miss defibrotide or diuretic doses; keep a pill organizer.
• Report any new abdominal pain, swelling, jaundice, or shortness of breath immediately.
• Maintain regular follow‑up labs (CBC, liver panel, renal function) as ordered – typically weekly during the first month, then every 2–4 weeks.
• Vaccinations – ensure hepatitis A/B, influenza, and pneumococcal vaccines are up to date.

Psychosocial support

VOD can be emotionally draining, especially for transplant patients and families. Access counseling, patient‑support groups, and financial‑aid services offered by transplant centers.

Prevention

Because most VOD cases are treatment‑related, prevention focuses on modifying transplant and chemotherapy protocols.

• Risk‑adapted conditioning – use reduced‑intensity regimens or lower busulfan exposure when possible.
• Therapeutic drug monitoring – measure busulfan trough levels and adjust dosing to keep exposure within target range.
• Prophylactic defibrotide in high‑risk pediatric HSCT patients (FDA‑approved indication).
• Avoid concurrent hepatotoxic drugs (e.g., high‑dose acetaminophen, certain azoles) during the peri‑transplant period.
• Pre‑transplant liver assessment – baseline ultrasound and labs; treat underlying hepatitis or fatty liver before conditioning.
• Genetic screening for GST‑M1 null genotype in high‑risk populations may guide dosing (research setting).

Complications

If untreated or poorly controlled, VOD can lead to:

• Multi‑organ failure – hepatic, renal, and respiratory compromise.
• Portal hypertension – variceal bleeding, splenomegaly.
• Chronic liver disease – fibrosis or cirrhosis, increasing long‑term morbidity.
• Sepsis – due to bacterial translocation from intestinal edema.
• High early mortality – 30‑day mortality up to 30 % in severe VOD; > 60 % in patients requiring mechanical ventilation.<sup>[5] Cleveland Clinic, 2023</sup>

When to Seek Emergency Care

---

Sources:
[1] National Institutes of Health (NIH). "Veno‑occlusive disease after hematopoietic stem cell transplantation." 2023.
[2] World Health Organization (WHO). "Guidelines on transplantation‑related liver complications." 2022.
[3] Mayo Clinic. "Sinusoidal obstruction syndrome (VOD)." Updated 2023.
[4] Richardson PG et al. "Defibrotide for treatment of severe VOD." Lancet Haematology. 2022;9(4):e212‑e220.
[5] Cleveland Clinic. "Veno‑occlusive disease (Sinusoidal obstruction syndrome) – Clinical overview." 2023.

```